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Objectives: The aim of this study was to determine the frequency 
of venous thromboembolism in critically ill coronavirus disease 
2019 patients and associate a degree of inflammatory marker ele-
vation to venous thromboembolism development.
Design: An observational study that identified patients with severe 
coronavirus disease 2019 between March 12, 2020, and March 
31, 2020. Data reported are those available through May 6, 2020.
Setting: A multicenter study including three Indianapolis area ac-
ademic hospitals.
Patients: Two-hundred forty consecutive patients with confirmed 
severe acute respiratory syndrome coronavirus 2 infection were 
admitted to one of three hospitals. One-hundred nine critically ill 
coronavirus disease 2019 patients admitted to the ICU were in-
cluded in the analysis.
Interventions: All patients received routine subcutaneous chem-
ical venous thromboembolism prophylaxis.
Measurements and Main Results: The primary outcome of this 
study was to determine the frequency of venous thromboem-
bolism and the degree of inflammatory and coagulation marker 
 elevation associated with venous thromboembolism development.
Descriptive statistics outlined the frequency of venous 
 thromboembolism at any time during severe coronavirus disease 
2019. Clinical course and laboratory metrics were compared 
between patients that developed venous thromboembolism and 
patients that did not develop venous thromboembolism. Hyperco-
agulable thromboelastography was defined as two or more hyper-
coagulable parameters.
Main Results: One-hundred nine patients developed severe co-
ronavirus disease 2019 requiring ICU care. The mean (± sd) age 
was 61 ± 16 years and 57% were male. Seventy-five patients 
(69%) were discharged home, 7 patients (6%) remain in the hos-
pital, and 27 patients (25%) died. Venous thromboembolism was 
diagnosed in 31 patients (28%) 8 ± 7 days after hospital admis-
sion, including two patients diagnosed with venous thromboem-
bolism at presentation to the hospital. Elevated admission d-dimer 
and peak d-dimer were associated with venous thromboembolism 
development (p < 0.05). d-dimer greater than 2,600 ng/mL pre-
dicted venous thromboembolism with an area under the receiver 
operating characteristic curve of 0.760 (95% CI, 0.661–0.858; 
p < 0.0001), sensitivity of 89.7%, and specificity of 59.5%. 
Twelve patients (11%) had thromboelastography performed and 
58% of these patients had a hypercoagulable study. The calcu-
lated coagulation index was hypercoagulable in 50% of patients 
with thromboelastography.
Conclusions: These data show that coronavirus disease 2019 
results in a hypercoagulable state. Routine chemical venous 
thromboembolism prophylaxis may be inadequate in preventing 
venous thromboembolism in severe coronavirus disease 2019. 
(Crit Care Med 2020; XX:00–00)
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The novel severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) has resulted in a pandemic passing three million worldwide cases of coronavirus 
disease 2019 (COVID-19) with an associated case-fatality 
rate of 6.9% (1). The first death from COVID-19 in the state 
of Indiana was reported on March 16; 65 deaths and 2,565 
cases were confirmed by March 31 (2). Severe COVID-19 is DOI: 10.1097/CCM.0000000000004466
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characterized by acute respiratory failure often culminating in 
the need for mechanical ventilation (3–6). Studies have associ-
ated increased acute phase reactants and inflammatory mark-
ers with severe COVID-19 (3–5, 7–10). Abnormal coagulation 
parameters have additionally been associated with severe or 
fatal COVID-19 (11–13). These reports describe a biochemical 
profile suspicious for a prothrombotic and hypercoagulable 
state characterized by significant elevations in fibrinogen and 
a rapid unexpected ascent of serum d-dimer. This degree of 
profound systemic inflammation has a well-known associa-
tion to a hypercoagulable state (14). These findings, and an-
ecdotal clinical experience, have generated the hypothesis that 
a prothrombotic state may play a dominant pathophysiologic 
role in severe or fatal COVID-19. Supporting this thesis is a 
study from China describing decreased mortality in critically 
ill patients receiving prophylactic anticoagulation with low-
molecular-weight heparin (15).
Profound systemic inflammation, critical illness, immo-
bility, and organ failure are documented risk factors for a 
prothrombotic and hypercoagulable state (16–18). Recent 
autopsy reports in patients with COVID-19 identified car-
diac and pulmonary microvascular thrombosis (19), support-
ing clinical suspicion for this pathophysiologic mechanism in 
COVID-19 shared among physicians on preprint platforms 
and social media. The frequency of venous thromboembolism 
(VTE) in critically ill patients with COVID-19, including deep 
vein thrombosis (DVT) and pulmonary embolism (PE), is be-
coming better understood, ranging from 25% to 27% in recent 
publications (12, 13). Thromboelastography is a dynamic eval-
uation of the viscoelastic properties of whole blood throughout 
the clot formation and lysis process, allowing for quantitative 
measurement of clot formation kinetics (20, 21). In various 
clinical circumstances including critical illness, a hypercoag-
ulable thromboelastography profile has been associated with 
increased thrombotic risk; however, thromboelastography has 
not been explored in patients with severe COVID-19.
The aim of this study was to determine the frequency of 
VTE in critically ill COVID-19 patients and associate a degree 
of inflammatory marker elevation to VTE development.
MATERIALS AND METHODS
Study Population
All patients with laboratory-confirmed SARS-CoV-2 infection 
admitted to three Indianapolis area hospitals between March 
12 and March 31 were evaluated in this study. Patients less 
than 18 years old, imprisoned patients, pregnant patients, and 
patients who elected for comfort care on arrival were excluded 
from analysis. All data available through May 6, 2020, were 
included.
Two-hundred forty adult patients were admitted; 122 
patients had mild/moderate COVID-19 and 118 patients had 
severe/fatal COVID-19. Definitions of COVID-19 severity are 
defined in subsequent text. Nine patients with severe COVID-
19 elected for comfort care only and were excluded from the 
analysis, resulting in 109 patients meeting inclusion criteria 
(Fig. 1). Twelve patients with thromboelastography were in-
cluded in a subgroup analysis. The Indiana University (IU) 
Institutional Review Board (IRB) approved the conduct of 
this study (IRB Study Number 2004134287) and deemed it 
exempt. Informed consent was waived, and anonymized data 
were analyzed.
The severity of COVID-19 is defined in subsequent text. 
All patients admitted with COVID-19 receive VTE chemo-
prophylaxis including either 5,000 U subcutaneous heparin 
every 8 hours, 40 mg enoxaparin daily, or 30 mg enoxaparin 
bid. Mild COVID-19 patients received best supportive treat-
ment. Moderate and severe COVID-19 patients, in addition 
to best supportive care, were treated with hydroxychloroquine 
400 mg orally every 12 hours for two doses, then 400 mg orally 
daily for four doses and azithromycin 500 mg IV daily for three 
doses. Acute respiratory distress syndrome (ARDS) was de-
fined according to the Berlin criteria (22). In patients with low 
pulmonary compliance, similar to traditional ARDS, standard 
ARDS Network strategy was used (23). Although standardized 
treatment protocols were applied generally, clinical judgment 
in individual cases dictated treatment strategies.
Study Definitions
Coexisting medical conditions and medications were recorded 
according to physician documentation at the time of hospital 
admission. Individual patient’s clinical examination findings, 
laboratory results, diagnostic imaging, treatment, and out-
comes were retrospectively reviewed.
Testing for COVID-19 was obtained in accordance with 
the Centers for Disease Control and Prevention (CDC) guide-
lines and clinical specimens were tested using the CDC’s assay 
(24). Testing occurred at the Indiana State Department of 
Health Laboratory from March 1 to March 19. All testing on 
and after March 20 was performed at the IU Health Pathology 
Laboratory.
Per institutional guidelines, mild COVID-19 was defined 
as Spo
2
 greater than 94% on room air with or without radi-
ographic evidence of pneumonia. Moderate COVID-19 was 
defined as a measured peripheral oxygen saturation (Spo
2
) less 
than or equal to 94% on room air with or without radiographic 
evidence of pneumonia. Severe COVID-19 was defined as Spo
2
 
less than or equal to 94% with respiratory rate greater than or 




 ratio less than or 
equal to 300 mm Hg. Any patient requiring mechanical venti-
lation was considered to have severe COVID-19.
Extremity DVT was diagnosed on four-extremity duplex 
ultrasound performed for clinical suspicion for venous throm-
bosis and defined as a loss of compressibility of the vein and 
abnormal or absent blood flow. PE was diagnosed on contrast-
enhanced cross-sectional imaging and defined as a filling de-
fect within the lumen of the pulmonary artery or its branches. 
All patients developing VTE at any time period during their 
illness were included in this analysis.
Kaolin activated thromboelastography was performed 
with the TEG5000 hemostasis analyzer (Haemonetics, 
Braintree, MA) and used heparinase coated cups. Each 
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thromboelastography assay included reaction time (R), ki-
netics (K), alpha angle (α), maximum amplitude (MA), and 
fibrinolytic activity 30 minutes after MA (LY30). A hyperco-
agulable thromboelastography was defined as two or more 
thromboelastography parameters beyond one sd of the age- 
and gender-matched controls (25). Of the individual throm-
boelastography parameters, a decreased R-time and K-time 
and an increased alpha angle and MA were considered hyper-
coagulable. A coagulation index (CI) was calculated for each 
thromboelastography and considered hypercoagulable if ele-
vated beyond the laboratory reference range.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 
Version 25.0 with deidentified data (IBM, Armonk, NY). Cate-
gorical variables are summarized as number with percentages. 
Variables with greater than 50% of patients missing data were 
not reported or included in the analysis. Continuous variables 
are reported as mean values with sd or median values with in-
terquartile range (IQR). No imputation was made for missing 
data. As appropriate, the chi-square test and Mann-Whitney 
U tests were performed to evaluate the bivariate relationship 
between variables of interest and COVID-19 outcomes. Re-
ceiver operator characteristic curves were plotted and Youden 
Index was used to determine optimal laboratory cutoff points. 
The discriminatory ability of these cutoff points to predict 
VTE was assessed by calculating the area under the curve 
(AUC), sensitivity, and specificity. p values of less than 0.05 
were accepted as statistically 
significant.
RESULTS
Demographic and Clinical 
Characteristics
One-hundred nine patients 
with confirmed SARS-CoV-2 
infection were treated for se-
vere COVID-19 requiring in-
tensive care. Demographic 
and clinical characteristics are 
shown in Table 1. Fifty-five 
patients (50%) were black, the 
mean age was 61 ± 16 years, 
and 57% of patients were male. 
The mean body mass index was 
34.8 ± 11.8 kg/m2. Sixty-one 
patients (56%) were admitted 
directly to the ICU. The mean 
duration of symptoms prior to 
ICU admission was 8 ± 5 days. 
Respiratory failure requiring 
mechanical ventilation devel-
oped in 103 patients (94%), 
cardiovascular failure requir-
ing vasopressors developed in 
70 patients (64%), and renal 
failure requiring renal replacement therapy (RRT) developed 
in 16 patients (15%).
As of May 6, 7 patients (6%) continue to receive inpatient 
treatment (non-ICU, n = 4; ICU, n = 3), 75 patients (69%) had 
been discharged from the hospital, and 27 patients (22%) died 
(Fig. 1). Patients discharged from the ICU had a median dura-
tion of 13 days (IQR, 9–17 d) of intensive care. Of the patients 
discharged from the hospital, the median hospital length of 
stay was 20 days (IQR, 16–27 d). Death occurred a median of 
11 days (IQR, 8–16 d) after hospital admission.
The median time to routine chemical VTE prophylaxis was 
hospital day 0 (IQR, 0–1 d) and included subcutaneous heparin 
every 8 hours (n = 61, 56%), enoxaparin daily (n = 26, 24%), 
or enoxaparin every 12 hours (n = 14, 13%). Seven patients 
(6%) were treated with full anticoagulation immediately upon 
admission for existing medical comorbidities (n = 4, 4%) or 
VTE diagnosed at presentation (n = 2, 2%). One patient was 
transferred from an outside hospital in which the timing of 
VTE prophylaxis initiation was unable to be determined.
Venous Thromboembolism
Of the 109 patients with severe COVID-19, 31 patients (28%) 
developed VTE. Two patients were diagnosed with VTE upon 
presentation to the hospital; the remaining 29 patients devel-
oped VTE while on routine chemical VTE chemoprophylaxis 
(n = 26) or on full anticoagulation for medical comorbidities 
(n = 3). Isolated DVT was diagnosed in 26 patients (84%) and 
isolated PE was diagnosed in one patient (3%); four patients 
Figure 1. Flow chart of study patients. COVID-19 = coronavirus disease 2019.
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TABLE 1. Clinical Characteristics of Patients at Baseline and Laboratory Values at 
Presentation
Baseline Variables Cohort (n = 109) No VTE (n = 78) VTE (n = 31)
Characteristic
 Mean age (range), yr 61 ± 16 (18–95) 62 ± 15 (18–83) 60 ± 17 (31–87)
 Sex, n (%)
  Male 62 (57) 42 (54) 20 (65)
  Female 47 (43) 36 (46) 11 (35)
 Race, n (%)
  Black 55 (50) 39 (50) 16 (52)
  White 44 (40) 33 (42) 11 (35)
  Other 10 (9) 6 (8) 4 (13)
 Mean body mass index, kg/m2 34.8 ± 11.8 34.8 ± 11.5 34.7 ± 12.7
 Comorbidity
  Hypertension 74 (68) 57 (73) 17 (55)
  Hyperlipidemia 59 (54) 46 (59) 13 (42)
  Diabetes mellitus 43 (39) 33 (42) 10 (32)
  Current smoker (within 30 d) 33 (30) 28 (36) 5 (16)
  Chronic obstructive pulmonary disorder 18 (16) 17 (22) 1 (3)
  Congestive heart failure 17 (15) 14 (18) 3 (10)
  Chronic kidney disease 16 (15) 13 (17) 3 (10)
  Asthma 16 (15) 13 (17) 3 (10)
 Mean duration of symptoms before admission, d 7 ± 5 7 ± 5 7 ± 3
 Mean duration of symptoms before  
ICU admission, d
8 ± 5 9 ± 5 8 ± 4
Laboratory data n, median (IQR) n, median (IQR) n, median (IQR)
 WBC count (per mm3) 109, 7,200 (5,100–9,800) 78, 7,000 (4,875–9,200) 31, 9,000 (5,150–11,450)
 Hemoglobin (g/dL) 109, 13.3 (12–14.5) 78, 13.4 (11.9–14.3) 31, 13.0 (12.4–14.8)
 Platelet count (per mm3) 109, 207,000  
(152,000–255,000)
78, 189,000  
(141,000–252,000
31, 224,000  
(191,000–261,000)
 Neutrophil-to-lymphocyte ratio 99, 6.5 (4.2–12.2) 71, 6.2 (3.8–11.8) 28, 7.7 (5.6–12.6)
 Creatinine (mg/dL) 109, 1.2 (0.9–1.9) 78, 1.30 (0.87–2.13) 31, 1.10 (0.89–1.42)
 Alanine aminotransferase (U/L) 103, 24 (18–44) 76, 23.5 (18–38.5) 27, 31 (19.5–47.5)
 Aspartate aminotransferase (U/L) 103, 39 (29.5–63) 76, 38 (27–58.5) 27, 51 (37–72.5)
 Hemoglobin A1c (%) 78, 6.4 (5.9–7.2) 57, 6.4 (5.9–7.2) 21, 6.1 (5.8–6.9)
 Lactate dehydrogenase (U/L) 91, 437 (348.5–573) 66, 426 (332–581) 25, 525 (431–568)
 Fibrinogen (mg/dL) 57, 535 (435–651) 36, 535 (425–681) 21, 528 (435–632)
 d-dimer (ng/mL) 84, 506 (321–973) 59, 464 (282–755) 25, 900 (432–3,570)
 Troponin (ng/mL) 81, 0.04 (0.03–0.10) 61, 0.03 (0.03–0.06) 20, 0.10 (0.05–0.22)
 Ferritin (ng/mL) 76, 579 (339–1,057) 52, 579 (339–1,050) 24, 638 (345–1,190)
 C-reactive protein (mg/dL) 91, 14.6 (10.1–22.7) 66, 14.8 (8.0–22.8) 25, 14.5 (12.5–21.3)
 Procalcitonin (ng/mL) 81, 0.23 (0.12–0.92) 58, 0.20 (0.14–0.58) 23, 0.26 (0.11–1.78)
 Interleukin-6 (pg/mL) 55, 14 (7.5–40.5) 39, 14 (7–40) 16, 14 (11–48)
IQR = interquartile range, VTE = venous thromboembolism.
Unless otherwise stated, means values are reported ± sd and median values are reported with IQR.
Bold values represent statistical significance with p < 0.05.
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had both DVT and PE (13%). Five DVT were associated with 
central venous catheters (CVCs) in the internal jugular vein 
(n = 3) and femoral vein (n = 2); however, in four of these 
patients, additional DVT were detected in locations remote 
from the CVC. The number of DVT identified per patient was 
3 ± 2. Of the 30 patients with DVT, the location of the DVT was 
most commonly the lower extremities (n = 18, 60%); however, 
upper extremity DVT and both upper and lower extremity 
DVT were diagnosed in six each (20%). The mean time from 
hospital admission to VTE diagnosis was 8 ± 7 days. Initial 
treatment for VTE included unfractionated heparin IV infu-
sion (n = 13, 42%), weight-based enoxaparin subcutaneously 
bid (n = 13, 42%), oral apixaban (n = 2, 6%), and unfraction-
ated heparin IV infusion with alteplase infusion (n = 2, 6%). In 
one patient, anticoagulation was contraindicated due to recent 
cerebrovascular accident.
On univariate analysis, the development of VTE was signif-
icantly associated with higher serum platelet count, aspartate 
aminotransferase, lactate dehydrogenase, d-dimer, and tro-
ponin concentrations at admission (Table 1). The frequency 
of VTE was no different in patients without or with respira-
tory failure requiring mechanical ventilation (33% vs 28%; 
p = 0.785), cardiovascular failure requiring vasopressors (26% 
vs 30%; p = 0.629), or renal failure requiring RRT (31% vs 
12.5%; p = 0.126). When comparing the peak serum concen-
tration of laboratory values in patients prior to VTE diagnosis to 
patients that did not develop VTE, increased d-dimer concen-
tration and decreased platelet counts were observed (Table 2).
Admission d-dimer concentration, peak d-dimer concen-
tration, and peak platelet count were plotted on a receiver op-
erating characteristic curve; the AUC, ideal laboratory cutoff 
points to detect VTE, and associated sensitivity and specificity 
are shown in Figure 2. A serum d-dimer concentration greater 
than 2,600 ng/mL (normal range, 0–292 ng/mL) was the test 
with the best discriminatory ability to detect VTE with an 
AUC of 0.760 (p < 0.0001) and a sensitivity and specificity of 
89.7% and 59.5%, respectively. Patients developing VTE had 
no difference in mortality (8/31, 26%) when compared with 
patients that did not develop VTE (19/78, 24%; p = 0.875).
Thromboelastography
Twelve patients (11%) had thromboelastography analyzed 
during their hospital stay and the mean value of each throm-
boelastography parameter is shown in Figure 3. Thromboelas-
tography was performed a median of 3.5 days (IQR, 1–6 d) 
after hospital admission and was performed for significantly 
elevated d-dimer (n = 8, 67%) or as a baseline prior to ex-
tracorporeal membrane oxygenation initiation (n = 3, 25%). 
In one patient (8%), thromboelastography was ordered due to 
persistent clotting of the RRT filter. Hypercoagulable throm-
boelastography (≥ 2 hypercoagulable thromboelastography 
parameters) were observed in 58% of patients and at least 
one thromboelastography parameter was hypercoagulable 
in 83% of patients. The most common hypercoagulable fea-
ture of thromboelastography was a decreased R-time in 67% 
of patients. The calculated CI was hypercoagulable in 50% 
of patients. The individual patterns of patients with hyper-
coagulable and nonhypercoagulable thromboelastography 
are shown in Figure 3. The mean d-dimer in patients with a 
hypercoagulable thromboelastography was 2,240 ± 599 ng/mL. 
Three patients (43%) with a hypercoagulable thromboelas-
tography developed VTE; however, one patient with a normal 
thromboelastography developed VTE.
DISCUSSION
In this series of 109 critically ill COVID-19 patients among 
three Indianapolis area hospitals, we report an extremely high 
frequency of VTE despite the prompt initiation of routine 
chemical VTE prophylaxis. Risk factors associated with VTE 
development included an elevated d-dimer at hospital pre-
sentation and an elevated d-dimer or decreased platelet count 
during intensive care. Thromboelastography documented 
hypercoagulability in the majority of patients in which it was 
TABLE 2. Peak Inflammatory and Coagulation Markers Prior to Venous Thromboembolism 
Diagnosis
Laboratory Value
No VTE (n = 80), 
n, Median (IQR)
VTE (n = 29),  
n, Median (IQR) p
Platelet count (per mm3) 78, 383,000 (291,000–472,000) 31, 294,000 (223,000–340,000) 0.001
Neutrophil-to-lymphocyte ratio 74, 12.2 (8.6–23.7) 29, 16.0 (9.3–21.0) 0.695
Lactate dehydrogenase (U/L) 75, 541 (401–708) 26, 534 (495–721) 0.870
Fibrinogen (mg/dL) 46, 680 (521–872) 23, 651 (465–771) 0.243
d-dimer (ng/mL) 74, 1,934 (695–3,573) 29, 4,046 (3,071–13,324) 0.00004
Ferritin (ng/mL) 70, 910 (447–1,775) 26, 1,022 (459–1,643) 0.882
C-reactive protein (mg/dL) 73, 24.3 (17.3–32.3) 27, 26.4 (13.6–33.4) 0.877
Procalcitonin (ng/mL) 63, 0.34 (0.20–1.93) 25, 0.66 (0.15–3.98) 0.554
IQR = interquartile range, VTE = venous thromboembolism.
Unless otherwise stated, median values are reported with IQR.
Bold values represent statistical significance with p < 0.05.
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performed. Mortality was not significantly different in patients 
developing VTE when compared with patients who did not 
 develop VTE.
We report a frequency of VTE of 28% in critically ill 
patients with COVID-19 and identified an elevated d-dimer 
at presentation and an elevated d-dimer or thrombocytopenia 
Figure 2. Receiver operator characteristic (ROC) curve, area under the curve, sensitivity, and specificity of d-dimer and platelet count to detect venous 
thromboembolism.
Figure 3. Thromboelastography in 12 patients with severe coronavirus disease 2019 (COVID-19). Values are reported as mean ± sd. CI = coagulation 
index, IU = Indiana University, K = kinetics, LY30 = fibrinolytic activity 30 minutes after maximum amplitude, MA = maximum amplitude, R = reaction 
time, TEG = thromboelastography, VTE = venous thromboembolism, α = alpha angle.
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during intensive care as risk factors for VTE development. 
About 5–10% of critically ill patients develop VTE; thus, the 
risk for VTE in critically ill patients with COVID-19 is about 
2.5–5 times higher than the general ICU population (26, 27). 
The frequency of VTE identified in the current study is similar 
to that reported in two recent studies from China (25%) and 
the Netherlands (27%) (12, 13) and similar to that reported 
in critically ill patients with severe acute respiratory syndrome 
(24%) during the outbreak in the early 2000s (28). COVID-19 
is associated with a profound systemic inflammatory response, 
hypercoagulable serum coagulation profile, organ failure, and 
immobility; thus, it is no surprise that the frequency of VTE is 
significant and higher than expected despite prompt initiation 
of routine chemical VTE prophylaxis. This study likely under-
estimates the true frequency of VTE in this population, as di-
agnostic evaluation for VTE was deferred to prevent untoward 
risk to healthcare workers and inpatients.
The mechanism by which critically ill patients with 
COVID-19 develop VTE at a higher frequency than the ge-
neral ICU population remains unclear, specifically whether a 
hypercoagulable state is induced by the degree of viremia and 
the virus itself, or if this is simply in response to the profound 
systemic inflammation and critical illness, which are known 
risk factors for VTE development (14, 16, 26, 27). The associa-
tion between elevated d-dimer and VTE development is likely 
representative of both the degree of systemic inflammation in 
critically ill COVID-19 patients and inappropriate activation 
of the coagulation cascade; however, the degree to which each 
of these components contribute to VTE development was not 
possible to determine in this study. The frequency of VTE in 
severe COVID-19, its risk factors, and outcomes warrant on-
going worldwide investigation, as COVID-19 will likely con-
tinue to contribute to worldwide morbidity and mortality for 
some years. Given the documented hypercoagulability and 
frequency of VTE in this population, consideration should 
be given to an escalated dose of chemical VTE prophylaxis 
using either weight-based or anti-factor-Xa guided dosing in 
COVID-19 patients with d-dimer greater than 728 ng/mL at 
presentation. In addition to this increased dosing of chemical 
VTE prophylaxis, critically ill patients with a d-dimer greater 
than 2,600 ng/mL (or > 10 times the upper limit of laboratory 
normal) should be evaluated with four-extremity duplex ul-
trasound; empiric anticoagulation in the setting of elevated 
d-dimer and presumptive diagnosis of VTE should be made on 
a case-by-case basis. Early detection of VTE and prevention of 
PE in patients with severe COVID-19 is paramount given the 
mounting clinical and autopsy evidence of lung microvascular 
and macrovascular thrombosis (12, 13, 19, 29), which plausibly 
may be contributing to the progressive and fatal hypoxemic 
respiratory failure in these patients without prompt initiation 
of adequate anticoagulation.
In this series of 12 patients with severe COVID-19 undergo-
ing thromboelastography analysis, 58% met objective criteria 
for hypercoagulability and 83% of patients had at least one 
hypercoagulable thromboelastography parameter. The most 
common hypercoagulable parameter was the reaction (R) time 
in 67% of patients. This suggests that SARS-CoV-2 infection 
and the associated systemic inflammation, in the most severe 
cases, results in activation of the coagulation cascade. Three 
of seven patients with a hypercoagulable thromboelastography 
went on to develop VTE; thus, larger volume, prospective stud-
ies may be warranted to evaluate this association further and 
define the utility of thromboelastography in COVID-19. Given 
the degree of inflammatory and coagulation marker elevation 
in severe COVID-19, serial thromboelastography analysis may 
provide useful insights as to which patients are at highest risk 
for microvascular and macrovascular thrombosis, potentially 
offering a window for improved and effective microvascular 
and macrovascular thrombosis prophylaxis. Our study cor-
roborates a recently published study that reported hyperco-
agulable thromboelastography in COVID-19 patients (30). 
Thromboelastography represents an objective metric (throm-
boelastography) to describe the hypercoagulability encoun-
tered in COVID-19 and provides a more complete picture of 
the coagulation cascade compared with traditional laboratory 
values. Large, prospective studies evaluating thromboelastog-
raphy could provide detailed insight into the abnormal coag-
ulation in COVID-19. Further, the potential role of platelet 
activation and aggregation in VTE development can be evalu-
ated with thromboelastography, providing an additional target 
for improved VTE prophylaxis with antiplatelet therapy. The 
current study and the study published by Panigada et al (30) 
were unable to evaluate platelet function in COVID-19, as 
thromboelastography with platelet mapping was not routinely 
performed. A multi-institutional observational study evalu-
ating the utility of serial thromboelastography in COVID-19 
is currently underway. Future investigation may evaluate for 
an association between thromboelastography parameters and 
anti-factor Xa guided VTE prophylaxis, as thromboelastogra-
phy may not be available at all institutions treating COVID-19 
patients.
Given the gravity and scope of the COVID-19 pandemic, 
rapid dissemination of significant clinical observations is 
paramount to improving patient outcomes; however, several 
limitations of this study deserve mention. Although this is a 
relatively large series, it is an observational study and the in-
herent bias introduced by a retrospective evaluation of any 
patient population is a limitation. The retrospective nature 
of this study precludes the ability to establish any causal re-
lationship between d-dimer concentration or platelet count 
and VTE development. Critically ill COVID-19 patients often 
had multiple CVCs simultaneously and/or at different time 
points throughout their treatment and the location of CVC as 
a risk factor for VTE development was unable to be evaluated. 
Measurement of prothrombin time was not included in the in-
stitutional protocol at the time of this study and not routinely 
performed, thereby preventing the ability of this study to eval-
uate disseminated intravascular coagulation. Only critically 
ill COVID-19 patients were included in this study; therefore, 
this study lacked a comparator group of ICU patients without 
COVID-19 in which to compare VTE frequency. The current 
study did not evaluate the degree of viremia as a risk factor for 
Copyright © 2020 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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VTE and this should be considered in future studies. The small 
number of patients with thromboelastography analysis may 
not accurately reflect the trends of the entire cohort and more 
detailed analysis is warranted. Given the number of patients 
with thromboelastography data, we were unable to associate 
thromboelastography parameters to VTE. The number of 
comparisons was intentionally kept to a minimum to avoid the 
introduction of type II error. Finally, Patients with sudden clin-
ical deterioration and death were not evaluated postmortem 
for the development of VTE.
CONCLUSIONS
These data show that SARS-CoV-2 infection results in systemic 
hypercoagulability resulting in VTE. Although current data on 
outcomes in patients receiving therapeutic anticoagulation in 
COVID-19 are lacking, it is apparent that routine chemical 
VTE prophylaxis may be inadequate in preventing thrombotic 
complications in severe COVID-19.
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